Lv1
30 积分 2023-03-19 加入
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
5个月前
已完结
Developing multiple EGFR-mutant lung cancers
5个月前
已关闭
Characterization of the generic mutant p53-rescue compounds in a broad range of assays
5个月前
已完结
Drugging p53: Barriers, Criteria, and Prospects
5个月前
已完结
Nanoreceptors take down mutant p53
1年前
已完结
Nanoreceptors promote mutant p53 protein degradation by mimicking selective autophagy receptors
1年前
已完结
Translating p53-based therapies for cancer into the clinic
1年前
已完结
The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic
1年前
已完结
Pharmacological reactivation of p53 in the era of precision anticancer medicine
1年前
已完结
Lung cancer in patients who have never smoked — an emerging disease
1年前
已完结
皖公网安备34019202002308
